01Approach to the Critical Patient/attcp63

Immediate priorities

›Airway and breathing threats

›Right pleural effusion or empyema

›Thoracic extension of abscess

›Decreased breath sounds at right base

›Oxygenation failure

›SpO2 < 90% on room air

›PaO2 < 60 mmHg

›Diaphragmatic irritation

›Right pleuritic chest pain

›Referred right shoulder pain

›Circulation and rupture threats

›Shock physiology

›SBP < 90 mmHg

›MAP < 65 mmHg

›Intraperitoneal rupture

›Peritoneal signs

›Abdominal rigidity and distention

›Pericardial rupture from left-lobe abscess

›Tamponade physiology

›Muffled heart sounds and JVD

›If hemodynamic instability with rupture, immediate resuscitation and surgical consult

›Large-bore IV access

›Type and crossmatch

›Sepsis and source threats

›Sepsis screening

›Suspected infection with organ dysfunction

›Lactate >= 2 mmol/l

02History/hx65

Presentation pattern

›Core syndrome

›Fever

›Present in 77% to 100% of cases

›Night sweats

›Right upper quadrant or epigastric pain

›Constant dull aching quality

›Pleuritic right chest component

›Referred right shoulder pain

›Diaphragmatic irritation source

›Worse with deep inspiration

›Onset and timeline

›Subacute onset over 2 to 4 weeks

›About 80% present in this window

›Cough common at presentation

›Delayed presentation after endemic exposure

›Months to years after travel

›Reactivation of latent infection

›Associated symptoms

›Gastrointestinal

›Nausea and vomiting

›Diarrhea in only 10% to 35%

›Constitutional

›Anorexia

›Weight loss in chronic cases

Risk factors

›Host and demographic factors

›Male sex

03Physical Exam/exam45

Vitals and general

›Stability snapshot

›Temperature

›Fever in 77% to 100% of cases

›High fever as severity marker

›Heart rate

›Tachycardia common

›Rising trend with sepsis

›Blood pressure

›SBP < 90 mmHg suggests rupture or sepsis

›MAP < 65 mmHg

›General appearance

›Ill and febrile

›Diaphoresis

›Discomfort with movement

›Volume status

›Dry mucosa if diarrhea

›Tachycardia with hypovolemia

Abdominal and hepatic exam

›Hallmark findings

›Tender hepatomegaly

›Point tenderness over the liver

›Tenderness in intercostal spaces

›Hepatic percussion tenderness

›Below the right costal margin

›Reproducible focal tenderness

›Rupture screen

›Peritoneal signs

04Differential Diagnosis/ddx46

Hepatic abscess and mass mimics

›Pyogenic liver abscess

›ICD-10 K75.0

›Age over 50 years

›Diabetes and biliary disease

›Distinguishing features

›Jaundice and multiple abscesses

›Negative amebic serology

›Hepatocellular carcinoma

›Necrotic hepatoma

›Cirrhosis or hepatitis B or C

›Elevated alpha-fetoprotein

›Imaging features

›Arterial enhancement

›Washout pattern

›Echinococcal hydatid cyst

›Usually incidental

›Often afebrile

›Eosinophilia possible

›Aspiration caution

›Anaphylaxis risk

›Daughter cysts on imaging

›Hepatic metastases

›Known primary malignancy

›Multiple lesions

›Constitutional symptoms

Acute abdomen and thoracic mimics

›Biliary and gastric

05Laboratory Tests/lt56

Hematology and inflammation

›Complete blood count

›Leukocytosis

›Mild to moderate elevation

›Without eosinophilia

›Anemia

›Mild and chronic disease pattern

›Normocytic

›Inflammatory markers

›Elevated ESR

›Nonspecific support

›Trends with response

›Elevated CRP

›Baseline then trend

›Falls with treatment response

Hepatic and metabolic panel

›Liver function tests

›Acute ALA pattern

›Elevated ALT

›Normal alkaline phosphatase

›Chronic ALA pattern

›Elevated alkaline phosphatase

›Normal ALT

›Bilirubin

›Usually normal

›Elevation suggests pyogenic abscess

›Other chemistries

›Albumin

06Diagnostic Tests/dt63

Scoring Systems

›Severity and sepsis stratification

›qSOFA

›RR >= 22 per minute

›SBP <= 100 mmHg

›Altered mental status

›SIRS criteria

›Temperature and heart rate

›WBC and respiratory rate

›Lactate-based perfusion assessment

›>= 2 mmol/l organ hypoperfusion

›Repeat after resuscitation

›Abscess risk descriptors

›Size thresholds

›Abscess > 5 cm high rupture risk

›Left-lobe location pericardial risk

›Limitations

›No validated ALA-specific score

›Clinical trajectory supersedes single value

›ACEP Level C recommendation for adjunct use

MRI

›MRI abdomen role

›Excellent sensitivity

›Rarely needed acutely

›Problem solving for indeterminate lesions

›Characterization indications

›Differentiate abscess from tumor

›Assess vascular or biliary involvement

07Disposition/dispo31

Level of care selection

›Admission indications

›All newly diagnosed ALA generally admitted

›Therapy initiation and monitoring

›Imaging confirmation

›Need for percutaneous drainage

›Diagnostic uncertainty

›Large or high-risk abscess

›Inability to tolerate oral medications

›Persistent vomiting

›IV metronidazole requirement

›ICU indications

›Hemodynamic instability or sepsis

›Vasopressor requirement

›Rising lactate despite resuscitation

›Signs of rupture

›Peritonitis

›Pericardial involvement

Discharge criteria and follow up

›Discharge criteria

›Clinical improvement

›Afebrile and improving pain

›Tolerating oral medications

›Safe outpatient plan

›Reliable follow-up arranged

›Luminal agent prescribed for completion

›Follow up plan

›Clinical reassessment within 1 to 2 weeks

08Treatment/t71

Initial stabilization

›Supportive measures

›IV fluids for hypoperfusion

›Crystalloid boluses

›Reassess perfusion

›Antipyretics and analgesia

›Acetaminophen

›Avoid hepatotoxic dosing

›Hemodynamic monitoring if septic

›Continuous vitals

›Lactate trend

Medical therapy

›Tissue amebicide mainstay

›Metronidazole

›750 mg PO or IV every 8 hours for 7 to 10 days

›Class I recommendation as first-line therapy

›Cure rates approach 95%

›Tinidazole alternative

›2 g PO daily for 3 to 5 days

›Better tolerated and shorter course

›Not always available in the US

›Expected response

›Fever and pain improve within 72 to 96 hours

›More than 50% size reduction within 1 week

›Luminal agent after tissue amebicide

›Paromomycin

›25 to 35 mg/kg/day divided every 8 hours for 7 days

›Start after completing metronidazole

09Special Populations/sp39

Pregnancy

›Pregnancy considerations

›Antimicrobial selection

›Metronidazole used when benefits outweigh risks

›Avoid in first trimester when possible

›Luminal agent

›Paromomycin poorly absorbed and preferred

›Defer until after delivery if stable

›Imaging approach

›Ultrasound first-line

›CT only when essential

›Maternal monitoring

›Maintain oxygenation

›Fetal monitoring when viable

Geriatric

›Older adult features

›Atypical presentation

›Blunted fever response

›Higher index for pyogenic abscess

›Overlapping comorbidity

›Diabetes and biliary disease

›Broaden differential

›Medication risk

›Renal and hepatic dosing adjustment

›QT prolongation risk higher

›Disposition bias toward admission

›Frailty

›Limited home supports

10Background/b58

Epidemiology

›Frequency and burden

›Most common extraintestinal amebiasis

›Hematogenous portal spread of trophozoites

›Entamoeba histolytica etiology

›Demographic distribution

›Male predominance 10 to 12 : 1

›Reproductive age 20 to 40 years

›Geographic burden

›Endemic in Indian subcontinent and Southeast Asia

›Africa and Central and South America

›Outcomes

›Mortality

›Less than 1% with early treatment

›Cure rates approach 95%

›Severity stratification

›Uncomplicated majority

›Complicated with rupture or superinfection

Pathophysiology

›Mechanisms

›Colonic invasion

›Trophozoites breach colonic mucosa

›Flask-shaped ulcers

›Portal dissemination

›Hematogenous spread via portal vein

›Right lobe predominance

›Tissue necrosis

›Liquefactive hepatic necrosis

11Patient Discharge Instructions/pdi20

copy discharge instructions

›Amebic liver abscess home care

›Take all antibiotics exactly as prescribed until finished

›Complete the second medicine that clears the intestine even after you feel well

›No alcohol during treatment and for at least 3 days after

›Rest and drink plenty of fluids

›Warning signs to return to the ER

›Worsening or returning fever after improvement

›Increasing belly pain, hardness, or swelling

›Chest pain or trouble breathing

›Lightheadedness or fainting

›Yellowing of the skin or eyes

›Vomiting that prevents keeping fluids down

›Expected recovery

›Fever and pain should ease within 3 to 4 days

›Contact your clinician if not improving by day 4 or 5

›The abscess shrinks slowly over several months on scans

›Follow up and prevention

›Clinic follow-up within 1 to 2 weeks

›Use safe drinking water and wash food well

›Practice good hand hygiene to prevent reinfection

12References/r15

Guidelines and key sources

›Key reviews and studies

›Kumar R et al. Amebic Liver Abscess: An Update. World Journal of Hepatology 2024

›Haque R et al. Amebiasis. New England Journal of Medicine 2003

›Stanley SL. Amoebiasis. Lancet 2003

›Diagnostic and imaging evidence

›Ralls PW et al. Sonographic Features of Amebic and Pyogenic Liver Abscesses 1987

›Lodhi S et al. Features Distinguishing Amoebic From Pyogenic Liver Abscess: 577 Adult Cases 2004

›Hoffner RJ et al. Common Presentations of Amebic Liver Abscess. Annals of Emergency Medicine 1999

›Treatment and microbiology evidence

›Chavez-Tapia NC et al. Cochrane review percutaneous procedure plus metronidazole versus metronidazole alone 2009

›Miller JM et al. IDSA and ASM Microbiology Laboratory Utilization Guide 2024

›Gupta S et al. Amebiasis and Amebic Liver Abscess in Children. Pediatric Clinics of North America 2022

›Coding standards

›ICD-10 A06.4 amebic liver abscess

›SNOMED CT amebic liver abscess disorder concept

Evidence & Review

Evidence & Review